Discovery of a simplified deguelin analog as an HSP90 C-terminal inhibitor for HER2-positive breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nguyen, Cong-Truong | - |
dc.contributor.author | La, Minh Thanh | - |
dc.contributor.author | Ann, Jihyae | - |
dc.contributor.author | Nam, Gibeom | - |
dc.contributor.author | Park, Hyun-Ju | - |
dc.contributor.author | Park, Jung Min | - |
dc.contributor.author | Kim, Yoon-Jae | - |
dc.contributor.author | Kim, Ji Young | - |
dc.contributor.author | Seo, Jae Hong | - |
dc.contributor.author | Lee, Jeewoo | - |
dc.date.accessioned | 2021-11-16T17:40:59Z | - |
dc.date.available | 2021-11-16T17:40:59Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2021-08-01 | - |
dc.identifier.issn | 0960-894X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/127661 | - |
dc.description.abstract | A series of O-substituted analogs of the C-ring-truncated scaffold of deguelin designed as heat shock protein 90 (HSP90) C-terminal inhibitors were investigated as novel antitumor agents against human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Among the synthesized compounds, compound 37 displayed significant inhibition in both trastuzumab-sensitive and trastuzumab-resistant breast cancer cells with little cytotoxicity to normal cells. Mechanistic studies of compound 37 carried out by HSP90 alpha C-terminal inhibitor screening, the induction of the heat shock response and downregulation of HSP90 client proteins indicated that the antitumor activity of 37 in breast cancer cells could be attributed to the destabilization and inactivation of HSP90 client proteins by the binding of 37 to the C-terminal domain of HSP90. A molecular docking study of compound 37 with a HSP90 homology model indicated that its S-isomer fit well in the ATP binding site of the Cterminal domain, forming key interactions. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.subject | BIOLOGICAL EVALUATION | - |
dc.subject | SHOCK | - |
dc.subject | BINDING | - |
dc.subject | DOMAIN | - |
dc.title | Discovery of a simplified deguelin analog as an HSP90 C-terminal inhibitor for HER2-positive breast cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Seo, Jae Hong | - |
dc.identifier.doi | 10.1016/j.bmcl.2021.128134 | - |
dc.identifier.scopusid | 2-s2.0-85107123415 | - |
dc.identifier.wosid | 000661400500002 | - |
dc.identifier.bibliographicCitation | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, v.45 | - |
dc.relation.isPartOf | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | - |
dc.citation.title | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | - |
dc.citation.volume | 45 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Organic | - |
dc.subject.keywordPlus | BIOLOGICAL EVALUATION | - |
dc.subject.keywordPlus | SHOCK | - |
dc.subject.keywordPlus | BINDING | - |
dc.subject.keywordPlus | DOMAIN | - |
dc.subject.keywordAuthor | HER2-positive breast cancer | - |
dc.subject.keywordAuthor | Trastuzumab-resistant breast cancer | - |
dc.subject.keywordAuthor | Human epidermal growth factor receptor 2 | - |
dc.subject.keywordAuthor | Eat shock protein 90 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.